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Abstract
Background: The dietary agent sulforaphane (SFN) has been reported to induce nuclear factor erythroid 2
(NF-E2)-related factor 2 (Nrf2)-dependent pathways as well as inhibiting histone deacetylase (HDAC) activity.
The current investigation sought to examine the relationships between Nrf2 status and HDAC expression in
preclinical and translational studies.
Results: Wild type (WT) and Nrf2-deficient (Nrf2−/+) mice were treated with the colon carcinogen 1,2-
dimethylhydrazine (DMH) followed by 400 ppm SFN in the diet (n = 35 mice/group). WT mice were more susceptible
than Nrf2−/+ mice to tumor induction in the colon. Tumors from WT mice had higher HDAC levels globally and locally
on genes such as cyclin-dependant kinase inhibitor 2a (Cdkn2a/p16) that were dysregulated during tumor
development. The average tumor burden was reduced by SFN from 62.7 to 26.0 mm3 in WT mice and from
14.6 to 11.7 mm3 in Nrf2−/+ mice. The decreased antitumor activity of SFN in Nrf2−/+ mice coincided with
attenuated Cdkn2a promoter interactions involving HDAC3. HDAC3 knockdown in human colon cancer cells
recapitulated the effects of SFN on p16 induction. Human subjects given a broccoli sprout extract supplement
(200 μmol SFN equivalents), or reporting more than five cruciferous vegetable servings per week, had increased p16
expression that was inversely associated with HDAC3 in circulating peripheral blood mononuclear cells
(PBMCs) and in biopsies obtained during screening colonoscopy.
Conclusions: Nrf2 expression varies widely in both normal human colon and human colon cancers and likely
contributes to the overall rate of tumor growth in the large intestine. It remains to be determined whether
this influences global HDAC protein expression levels, as well as local HDAC interactions on genes dysregulated during
human colon tumor development. If corroborated in future studies, Nrf2 status might serve as a biomarker of HDAC
inhibitor efficacy in clinical trials using single agent or combination modalities to slow, halt, or regress the progression
to later stages of solid tumors and hematological malignancies.
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Background
Histone deacetylase (HDAC) enzymes have emerged as
important regulators of cancer development [1, 2].
Downregulation of specific HDACs can increase global
histone acetylation, turn-on epigenetically silenced
genes, and trigger cell cycle arrest, apoptosis, or differen-
tiation in cancer cells [3–5]. Pan-HDAC inhibitors are
currently undergoing clinical evaluation as anticancer
agents, but the quest continues for more specific HDAC
inhibitors with improved efficacy towards hematological
and solid tumors [5].
We reported that a natural compound, sulforaphane
(SFN), targets HDAC3 for protein turnover in human
colon cancer cells [6–12]. SFN is obtained from broccoli
and other cruciferous vegetables that are rich sources of
the precursor, glucoraphanin [13, 14]. SFN was first
identified as an inducer of phase 2 detoxification en-
zymes, acting via the nuclear factor erythroid 2 (NF-E2)-
related factor 2 (Nrf2) signaling pathway [15]. However,
Nrf2 in certain circumstances can preserve rather than
attenuate cancer phenotypes [16, 17].
The current investigation sought to examine the re-
lationships between Nrf2 status and HDAC expression
in a widely used model of colon carcinogenesis [18, 19].
Preclinical experiments included post-initiation SFN treat-
ment and highlighted a role for HDAC3 in regulating
cyclin-dependant kinase inhibitor 2a (Cdkn2a/p16) ex-
pression. The findings were extended to human subjects
according to their cruciferous vegetable consumption or
supplement intake.
Results
Dosing schedule and HDAC3 levels dictate anticancer
outcomes in the colon
1,2-Dimethylhydrazine (DMH) was administered for
10 weeks, and 1 week later SFN was given in the diet by
continuous or alternating daily dosing schedules (Fig. 1a).
There was a significant reduction in tumor multiplicity
and tumor burden only after continuous SFN treat-
ment (Fig. 1b, c). In colon tumors, daily SFN lowered
HDAC activity (Fig. 2a) and HDAC3 protein expression
(Fig. 2b, c) while increasing global histone H4 acetylation
(Fig. 2b, c). The findings in vivo recapitulate prior obser-
vations on HDAC3 protein turnover by SFN in cell-based
assays [20]. Several SFN metabolites have been examined
in the context of the HDAC turnover mechanism
[11, 20, 21], namely, SFN-glutathione (SFN-GSH), SFN-
cysteine-glycine (SFN-CG), SFN-cysteine (SFN-Cys), and
SFN-N-acetylcysteine (SFN-NAC). These metabolites were
detected, as reported [22], in tissues of SFN-treated mice
(data not shown).
Nrf2 genetic background influences HDAC protein levels
in colon tumors
Continuous SFN treatment was used in a modified
protocol that employed fewer DMH doses and a longer
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Fig. 1 Continuous and alternating dosing schedules for dietary SFN in the DMH model. a Male ICR mice were injected i.p. with DMH (20 mg/kg),
once per week for 10 weeks (arrows). One week after completing the DMH treatment, mice were continued on standard AIN93 diet (no SFN) or
given AIN93 diet containing 400 ppm SFN either continuously (daily SFN, green box) or on alternate days (Alt SFN, stripes). b Tumor multiplicity
and c total tumor burden, i.e., the sum of individual tumor volumes, were determined for each animal at 25 weeks, and mean values were
calculated (dotted line). *P < 0.05 vs. no SFN controls
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post-initiation phase in wild type (WT, Nrf2+/+) and
Nrf2−/+ mice (Fig. 3a). The longer study duration of
35 weeks resulted in an average tumor burden of
62.7 mm3 in WT mice (Fig. 3b and Table 1, part B),
compared with 18.4 mm3 at 25 weeks (Table 1, part A).
Notably, in the 35-week study, DMH produced an aver-
age tumor burden of 14.6 mm3 in Nrf2−/+ mice (Fig. 3b
and Table 1, part B), compared with 62.7 mm3 in the
Nrf2+/+ controls. In SFN-fed mice, the average tumor
burden was reduced from 62.7 to 26.0 mm3 in WT mice
and from 14.6 to 11.7 mm3 in Nrf2−/+ mice (Fig. 3b and
Table 1, part B). In colon tumors, Nrf2 levels were sig-
nificantly lower in Nrf2−/+ vs. Nrf2+/+ mice, regardless of
SFN treatment (Fig. 3c).
Immunoblotting of tissue lysates from tumor and adja-
cent normal colon revealed that HDAC3 expression was
reduced by SFN treatment in WT mice (Fig. 4a), but not
in mice on the Nrf2−/+ background (Fig. 4b). In general,
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Fig. 2 SFN decreased HDAC activity and HDAC3 protein expression in mouse colon tumors. a HDAC activity in colon tumor lysates was determined
as described in “Methods” section. Mean values were calculated in each group (dotted line). *P < 0.05 vs. no SFN controls. b HDAC expression and
histone acetylation determined by immunoblotting. c Densitometry data for HDACs were normalized to β-actin, whereas acetylated histone H4K12
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Fig. 3 Antitumor activity of dietary SFN in Nrf2+/+ and Nrf2−/+ mice. a Nrf2+/+ (WT) or Nrf2−/+ mice were injected i.p. with DMH (20 mg/kg), once per
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HDAC expression was lower in colon tissues of Nrf2−/+
animals (compare y-axes of densitometry plots in Fig. 4a,
b). No treatment-related differences were detected for
HDAC3 mRNA levels or for other class I HDACs (data
not shown).
Nrf2 status impacts HDAC3 levels on p16 in mouse
colon tumors
Gene expression arrays differentiated between the genes
most altered by SFN treatment when comparing tumor
with adjacent normal colon (Fig. 5a). For the complete
list of genes and the respective fold changes, see Add-
itional file 1: Table S1. Scatter plots were generated with
an arbitrary cutoff of fivefold in either direction. When
tumors were compared with adjacent normal colon, cyc-
lin-dependant kinase inhibitor 2A (Cdkn2a/P16), a well-
known tumor suppressor, was surprisingly the most
highly overexpressed gene in the tumors of WT mice
(Fig. 5b). Estrogen receptor 1, alpha (Esr1), a nuclear
hormone receptor involved in the regulation of
eukaryotic gene expression that affects cellular prolifera-
tion and differentiation in target tissues, also was
highly expressed, whereas known tumor suppressors
cyclin-dependant kinase 1A (Cdkn1a/p21), serine peptid-
ase inhibitor (serpin b5), and oncogenes such as Met
proto-oncogene (Met), and protein kinase C, alpha
Table 1 Summary of mouse tumor studies
Treatment Colon tumor incidence Multiplicity (tumors/mouse) Tumor burden (mm3) Average food consumption
(g/day)
Mouse weight at end
of study (g)
A 25-week study
No SFN 23/24 (95.8 %) 5.3 ± 2.8 18.4 ± 15.9 3.5 ± 0.8 45.3 ± 4.9
Daily SFN 15/21 (71.4 %) 2.8 ± 2.5* 7.1 ± 7.2* 3.9 ± 1.3 43.6 ± 3.8
Alt SFN 10/11 (90.9 %) 7.2 ± 4.4 22.6 ± 18.3 3.8 ± 1.0 44.0 ± 2.9
B 35-week study
−SFN (Nrf2+/+) 28/28 (100 %) 7.0 ± 3.7 62.7 ± 53.5 3.7 ± 0.7 51.3 ± 6.5
+SFN (Nrf2+/+) 27/28 (96.4 %) 5.7 ± 4.0 26.0 ± 30.2* 3.6 ± 1.5 44.7 ± 7.0
−SFN (Nrf2−/+) 31/32 (96.8 %) 4.0 ± 2.1 14.6 ± 24.8 3.1 ± 0.6 45.2 ± 8.0
+SFN (Nrf2−/+) 28/31 (90.3 %) 3.0 ± 2.1 11.7 ± 13.5 3.2 ± 0.5 43.8 ± 6.5
*P < 0.05 vs. corresponding control mice given no dietary SFN
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Fig. 4 SFN decreased HDAC3 protein expression in colon tumors of Nrf2+/+ but not Nrf2−/+ mice. a HDAC expression was immunoblotted in
tumor (T) and adjacent normal-looking colon (N) of WT mice, with densitometry data normalized to β-actin. b The corresponding data for Nrf2−/+
mice. Data are given as mean ± SD (n = 3); *P < 0.05, **P < 0.01 for control diet vs. SFN treatment. In addition to global reductions in HDAC3,
marked loss of HDAC3 on gene targets was examined (see Fig. 6)
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(Prkca) were underexpressed in the tumor. On the
Nrf2−/+ background (Fig. 5c), tumor suppressor genes
such as Cdkn2a and transformation-related protein 53
(Tp53), as well as reported oncogenic factors E26
avian leukemia oncogene 1,5′ domain (Ets1) and
insulin-like growth factor 2 receptor (Igf2r) were over-
expressed, whereas underexpressed genes included tumor
suppressor genes cyclin-dependent kinase inhibitor 2B
(Cdkn2b/p15) and serpin b5. mutL homolog 1 (Mlh1),
which is known to be silenced in human colon cancer was
also attenuated in mouse colon tumors. SFN treatment
compressed the spread of altered genes (Fig. 5d, e), al-
though Cdkn2a/p16 levels remained consistently elevated,
especially in WT mice given SFN.
Candidates from the PCR arrays were validated by
quantitative reverse transcription PCR (qRT-PCR), con-
firming Cdkn2a/p16 as being among the most highly
overexpressed genes (Additional file 2: Figure S1). SFN
altered Cdkn2a/p16 mRNA expression in colon tumor
and adjacent normal-looking colon of WT and Nrf2−/+
mice (compare red arrows in Additional file 2: Figure S1,
A vs. B, C vs. D, E vs. F, and G vs. H). Interestingly, SFN
increased Cdkn2a/p16 mRNA levels in colon tumors
of WT mice but had the opposite effect in Nrf2−/+
mice (Fig. 6a). These findings were supported by im-
munohistochemical analysis of p16 protein expression
(Fig. 6b–e). Thus, high levels of p16 protein were detected
in tumors compared with adjacent normal colon, espe-
cially in WT mice fed with SFN (Fig. 6c, inset).
Based on prior reports linking Cdkn2a and HDAC3
[23–25], we performed chromatin immunoprecipitation
(ChIP) assays in vivo and observed HDAC3 interactions on
the p16 proximal promoter region to be lower in colon tu-
mors of Nrf2−/+ mice compared with WT (Fig. 6f, black vs.
grey bars), especially after SFN treatment (green bars). A
runt-related transcription factor 1 (Runx1) binding
site, ~10 Kb upstream of the p16 promoter [26], had
minimal HDAC3 interactions and served as a negative
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control for the ChIP assays (Fig. 6f, region “4”). Notably,
the findings for HDAC3-dependent regulation of p16 did
not represent a generic response of all highly dysregulated
genes; HDAC3 interactions on Esr1, for example, were un-
affected by SFN (Additional file 2: Figure S2).
p16 is regulated directly by HDAC3, but not Nrf2, in
human colon cancer cells
In human colon cancer cells, Cdkn2a mRNA expression
was induced 24 h after SFN treatment (Fig. 7a), and im-
munoblotting corroborated the increased expression of
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Rajendran et al. Clinical Epigenetics  (2015) 7:102 Page 6 of 12
p16 protein (Fig. 7b). RNAi-mediated knockdown of
HDAC3 also increased p16 levels, whereas the knock-
down of Kelch-like ECH-associated protein 1 (Keap1),
which releases Nrf2 from the cytoplasm to the nucleus
for gene activation, did not increase p16 expression.
Keap1 knockdown induced the Nrf2 target gene heme
oxygenase-1 (HO1, a positive control for Nrf2 activation)
to a similar extent as SFN treatment, whereas HDAC3
knockdown had no effect on HO1 (Fig. 7c). Knockdown
of Keap1 and HDAC3 was confirmed at the mRNA and
protein level (Fig. 7d, e). We conclude that Cdkn2a/p16
is an HDAC3-regulated gene that does not involve direct
Nrf2 interactions, whereas the reverse is true for HO1.
HDAC3 and p16 are reciprocally regulated in humans
after SFN intake
To examine these relationships in humans, healthy sub-
jects consumed a broccoli sprout extract (BSE) supple-
ment or placebo once a day for 7 days, and blood was
drawn at 0, 1, 3, and 6 h post-consumption on day 1
(first day of study) and day 7 (to study effects due to
dose accumulation, if any), and on days 8, 9, and 14 as a
follow-up to ensure systemic clearance of SFN and me-
tabolites (Fig. 8a). After consuming BSE (200 μmol SFN
equivalents), plasma levels of SFN metabolites peaked at
1–3 h, rapidly decreased at 6 h, and were undetectable
at 24 h (Fig. 8b, black symbols). The specific SFN metab-
olites were in agreement with prior studies [27] and
were higher on day 1 as compared to day 7 (Additional
file 3: Table S2). In a recent report [27], half the dose
(100 μmol SFN equivalents) given every 12 h produced
lower SFN tissue concentrations than in the present in-
vestigation. We infer that a single daily dose of 200 μmol
SFN equivalents might be necessary to elicit HDAC in-
hibitory responses in vivo.
In mice, a single oral dose of SFN reduced HDAC3
protein expression and increased p16 protein level in
splenocytes, supporting the use of these end points as
potential biomarkers in systemic tissues (Additional
file 2: Figure S3). Thus, HDAC3 and p16 protein ex-
pression changes also were examined in circulating
peripheral blood mononuclear cells (PBMCs) from hu-
man volunteers (Fig. 8c). HDAC3 was reduced as early
as 1 h after BSE consumption and continued to re-
main low up to 6 h later. Notably, the loss of HDAC3
coincided with increased p16 expression during this
time period. On day 7, HDAC3 levels returned to
baseline, whereas p16 remained elevated (Fig. 8c). This
implies that cross-talk between HDAC3 and p16 can
be uncoupled at later times, possibly via interactions
of p16 with alternative HDACs, histone acetyltransfer-
ases, and/or their co-regulators [20, 21]. For example,
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were determined as reported [27]. d Study design in screening colonoscopy patients. e Relative mRNA expression of p16 in subjects
reporting low (0–1 servings/week) vs. high (>5 servings/week) cruciferous vegetable intake. f Immunoblotting of colon biopsies, arranged
left to right according to cruciferous vegetable intake. g–i Associations between p16, HDAC3, AcH4K12, and Nrf2 normalized to β-actin
(relative densitometry of proteins in panel f)
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HDAC3/SMRT inhibition and turnover has been ob-
served to precede changes in other HDACs, such as
HDAC6 [20]. Lower SFN metabolite levels at day 7 vs.
day 1 hinted at a possible compensatory mechanism fol-
lowing repeated daily SFN intake. Further studies are
needed to examine the possible induction of pathways
that favor enhanced SFN metabolism and/or excretion.
Based on findings from the short-term intervention
trial with BSE, HDAC3 and p16 were examined in the
context of more typical human dietary intake patterns
(Fig. 8d). Patients scheduled for a screening colonoscopy
were stratified as high vs. low cruciferous vegetable con-
sumers based on a validated questionnaire [28]. In
PBMCs obtained immediately prior to colonoscopy, p16
mRNA levels were significantly higher for subjects
reporting >5 vs. 0–1 servings of cruciferous vegetables
per week (Fig. 8e). We next examined the corresponding
colon biopsies for selected proteins of interest, i.e., p16,
HDACs, and histone acetylation (Fig. 8f ). With higher
cruciferous vegetable intake, histone acetylation and
p16 expression were increased, whereas HDAC1 levels
were unchanged. Based on densitometry measurements of
immunoblots, a significant inverse association was ob-
served for p16 and HDAC3 in colon biopsies (Fig. 8g),
whereas p16 and acetyl histone H4 lysine 12 (AcH4K12)
(Fig. 8h) and HDAC3 and Nrf2 (Fig. 8i) were positively
correlated.
Discussion
SFN was first identified as a potent inducer of phase 2
enzymes, acting via the Nrf2 pathway to induce detoxifi-
cation pathways that favor carcinogen excretion and
elimination from the body [14, 15]. However, SFN also
can be effective in post-initiation protocols [29], inde-
pendent of carcinogen exposure. This is exemplified by
the tumor suppression observed for SFN in genetic
models, such as the adenomatous polyposis coli/multiple
intestinal neoplasia (ApcMin/+) mouse, in which HDAC
inhibition was identified as a contributing mechanism
[10]. Therefore, we examined the interplay between two
key mechanisms implicated in the SFN antitumor activ-
ity, namely, Nrf2 induction and HDAC inhibition. Al-
though pharmacological HDAC inhibitors have been
tested in preclinical models of colon cancer [30], the role
of Nrf2 was not examined. We specifically sought to test
the hypothesis that Nrf2 status might affect HDAC3
protein expression levels in colon tumors, and thus the
inhibitory response to SFN acting preferentially on
HDAC3 [20, 21].
As in the ApcMin/+ mouse [10, 31], SFN suppressed
tumorigenesis in the DMH model, and this was accom-
panied by reduced HDAC activity and HDAC3 protein
expression in the colon tumors. These findings are in
accordance with data from human colon cancer cells
showing HDAC inhibition by SFN and its metabolites
[11, 20], and by other dietary isothiocyanates [21], to in-
volve HDAC3 protein turnover. Metabolites implicated
in the HDAC3 turnover mechanism [11, 20, 21], such as
SFN-Cys and SFN-NAC, were detected in tissues of
SFN-treated mice, as reported [22]. The corroboration of
HDAC3 as a target of SFN in vivo is important con-
sidering the critical role of this HDAC in regulating
colon cancer growth and tumorigenesis [3]. Loss of
tumor suppression in mice fed with SFN on alternat-
ing days (Fig. 1) might be related to the inability to
sustain high enough SFN metabolite levels for effect-
ive HDAC3 inhibition. Indeed, SFN metabolites are
cleared within 24 h in mice [22], as in human sub-
jects consuming BSE (Fig. 8b).
Nrf2-deficient mice are generally more sensitive to
carcinogens and agents that trigger chronic inflamma-
tion [32–35]. However, Nrf2−/+ mice treated with DMH
and observed for up to 35 weeks had a significantly
reduced tumor burden and lower HDAC protein expres-
sion compared with WT animals. The differential re-
sponse to the carcinogen likely was not attributable to
genes that regulate DMH metabolism (Cyp2E1) or DNA
repair (Mgmt), since their expression was similar in WT
and Nrf2−/+ mouse colon (Additional file 2: Figure S4).
In a recent study using urethane to initiate lung tumors
[16], resistance to tumor growth was observed in Nrf2-
deficient mice compared with WT. The enhanced tumor
growth in WT mice adds to the discussion on pros vs.
cons of Nrf2 signaling in different stages of cancer
development [17, 36].
From the gene expression arrays, qRT-PCR and im-
munoblotting experiments, tumor suppressors p21 and
p15 were induced only marginally, if at all, by SFN in
the preclinical model reported here, in marked con-
trast to p16. For example, in gene expression arrays
(Additional file 1: Table S1), p21 and p15 were attenuated
slightly in the colon tumors from SFN-treated mice,
whereas p16 was induced greater than 20-fold. Although
p16 more typically is considered a tumor suppressor pro-
tein, high Cdkn2a/p16 levels have been detected in
mouse colon tumors induced by azoxymethane, a metab-
olite of DMH [37], and in human benign tumors and
high-grade malignancies [38]. Overexpression of p16 has
been linked to the so-called oncogene-induced senes-
cence (OIS) in benign tumors or as a mechanism to ar-
rest uncontrolled proliferation in advanced cancers [38].
Early upregulation of p16 in some tumors might repre-
sent an attempt to correct for one or more dysregulated
signaling pathways. We focused on p16 as a major target
dysregulated in DMH-induced colon tumors and noted
that SFN increased p16 expression in tumors of WT mice
but had the opposite effect in Nrf2−/+ mice. Based on evi-
dence that HDAC inhibition activates p16 [39–41], we
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confirmed HDAC3 interactions on p16 to be higher in
colon tumors of WT vs. Nrf2−/+ mice (Fig. 6f ), and in-
versely associated with p16 mRNA levels (Fig. 6a). In hu-
man colon cancer cells, HDAC3 knockdown increased
p16 levels to a similar extent as SFN treatment, whereas
Keap1 knockdown had no effect on p16 (Fig. 7). This
suggested that p16 is regulated by HDAC3 but is not a
direct target of Nrf2.
What, then, connects Nrf2 genetic background to
altered HDAC3 levels on p16? A working model can be
proposed (Additional file 2: Figure S5). We speculate
that Nrf2 deficiency in mice, through mechanisms that
remain to be clarified, attenuates the overall rate of
colon tumor growth and global HDAC levels within the
tumor. This in turn diminishes HDAC interactions on
key genes dysregulated during tumor development, re-
gardless of whether or not they are directly regulated by
Nrf2 binding. Mechanisms affecting promoter methyla-
tion and transcription factor access [42–45] might influ-
ence which genes are most altered, and the ultimate
response to SFN treatment.
The BSE supplement is being evaluated in several hu-
man trials (clinicaltrials.gov). In the current investiga-
tion, SFN metabolites were detected in plasma shortly
after BSE intake, and in circulating PBMCs, there was
increased p16 and transiently decreased HDAC3 expres-
sion. As predicted from the preclinical model, in human
colon biopsies HDAC3 was inversely associated with p16
(Fig. 8g), and positively correlated with Nrf2 (Fig. 8i).
We were interested in the variability of Nrf2 expression
in normal colon biopsies (Fig. 8f ). In The Cancer
Genome Atlas (TCGA) database [46], NFE2L2 (Nrf2)
levels also varied markedly in normal colon and in colon
tumors and were inversely correlated with Cdkn2a/p16
(Fig. 9), in accordance with data from cell-based, pre-
clinical, and translational studies reported here. We are
now recruiting additional human volunteers to obtain
both polyps and adjacent normal colon biopsies, seeking
to corroborate the proposed cross-talk between Nrf2,
HDAC3, and p16.
Conclusions
Nrf2 status in the mouse colon appears to serve as an
arbiter of overall colon tumor growth, HDAC protein
expression in colon tumors, and the response to HDAC
inhibitor treatment mediated by downstream molecular
targets such as p16. A key issue will be the extent to
which Nrf2 status influences HDAC levels and p16 ex-
pression at different stages of human colon cancer de-
velopment and the ultimate response to pan-HDAC or
HDAC-selective inhibitors. This could have implications
beyond the treatment of colorectal cancer, for example,
in other solid tumors and hematological malignancies
currently undergoing clinical evaluation with HDAC
inhibitors [47]. In the broad context of these various
clinical trials and their overall aims, we believe that Nrf2
status is worthy of further investigation as a possible
determinant of tumor growth and HDAC inhibitor
responsiveness.
Methods
Animals and diets
Male WT or Nrf2−/+ mice at 8–10 weeks of age were
randomized to 25 mice/group (pilot study) or 35
mice/group (main study). Tumors were induced by
1,2-dimethylhydrazine (DMH, Sigma-Aldrich), as re-
ported [19]. After DMH treatment, mice continued on
regular AIN93 diet for an additional week before admin-
istering AIN93 diet or AIN93 diet supplemented with
400 ppm D,L-SFN (Toronto Research Chemicals, Inc.),
either continuously or on alternating days. At end of the
study, the colon was removed, and tumors were scored
for number, size, and position by individuals blinded to
the treatment. Tumor volume was calculated using the
formula xy2 * 0.5 (x = long diameter, y = short diameter).
Total tumor burden per animal was calculated by adding
the individual tumor volumes. Tumor and adjacent
normal-looking tissue was removed and one portion was
fixed in 10 % buffered formalin, while the other portion
was flash-frozen in liquid nitrogen and stored at −80 °C.
The work was approved by the Institutional Animal Care
and Use Committee.
HDAC activity
HDAC activity was measured using the FLUOR DE LYS
assay, as reported [10, 20].
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Fig. 9 Nrf2 and p16 are inversely associated in human colon
tumors and normal colon. The Cancer Genome Atlas (TCGA,
https://tcga-data.nci.nih.gov/tcga/) was mined for NFE2L2 (Nrf2)
and CDKN2A (p16) mRNA expression data in colon tumors
(black) and normal colon (red)
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Immunoblotting
Frozen samples of colon tumors and adjacent tissue
were thawed and subjected to immunoblotting using the
methodology described previously [20, 21, 48]. Anti-
bodies were for HDAC1 and HDAC3 (Santa Cruz), p16
(Proteintech), acetyl histone H4K12 and histone H4
(Cell Signaling), and β-actin (Sigma-Aldrich).
PCR arrays and qPCR
RT2 Profiler arrays were run as per manufacturer’s in-
structions (SA Biosciences, Qiagen, Valencia, CA, USA)
on colon tumor samples (pooled, n = 6) and matched
controls (pooled, n = 6). From the threshold cycle (Ct)
value, the relative gene expression of each target was
normalized to human β-actin gene (ACTB) or murine
β-actin gene (Actb) (β-actin gene in human and
mouse, respectively). Two or more separate qRT-PCR
experiments were performed to validate targets of
interest, as reported [48].
ChIP assays
The ChIP-IT Express Enzymatic kit (Active Motif,
Carlsbad, CA) was used, as reported [49]. Frozen tissue
(100 mg) was cut into pieces, cross-linked with formal-
dehyde, and homogenized in order to isolate the nuclear
fraction. DNA fragmentation was performed via enzym-
atic shearing, using a proprietary cocktail (Active Motif )
that randomly cleaves between nucleosomes, generating
DNA fragments of ~500 bp. Ten microliters of fragmen-
ted chromatin was kept as input while the remaining
was immunoprecipitated (IP) with anti-HDAC3 antibody
(Santa Cruz). After reversing the cross-linking and pro-
teinase treatment, DNA was purified using QIAquick
PCR Purification kits (Qiagen). PCR was run on a
Roche LightCycler 480 II with preincubation for 5 min
at 95 °C, then 45 cycles at 95 °C for 10 s, 60 °C for 10 s,
and 72 °C for 10 s. Each experiment was repeated at least
twice.
Immunohistochemistry
Formalin-fixed paraffin-embedded mouse colon tumor
and adjacent normal tissue were processed for immu-
nohistochemistry as reported [48]. Slides containing
5 μm sections were rehydrated and placed in an
Autostainer (Dako). After primary antibody to p16
(Proteintech) for 30 min and One-Step HRP Polymer
anti-IgG (ImmunoBioscience) for 7 min, Nova Red (Vector
Labs) was applied for 5 min followed by hematoxylin
(Dako). Images were acquired on a Nikon E400 micro-
scope equipped with a CCD camera.
Knockdown experiments
HCT116 cells were obtained from American Type
Culture Collection (Manassas, VA, USA) and validated
as reported [50]. Cells were transfected for 48 h with
HDAC3 siRNA (Trilencer-27, OriGene), Keap1 siRNA
(Sigma-Aldrich), control siRNA (OriGene), or Lipofec-
tamine 2000 alone, using the manufacturer’s protocol
(Invitrogen).
Human studies
Phase “0” trial
A pilot intervention study was performed based on a
prior protocol [12]. Ten healthy subjects avoided crucif-
erous vegetables, starting 1 week before day 1 of the
study and continuing through day 14. After an overnight
fast, volunteers ate a standardized breakfast together
with a broccoli sprout extract (BSE) supplement
(IND #111736, 200 μmol SFN equivalents, n = 5) or a
placebo (n = 5), once a day for 7 days. BSE and pla-
cebo were obtained from Johns Hopkins University
(Baltimore, MD, USA), with SFN content validated
by LC-MS/MS, as reported [27]. The Institutional
Review Board (IRB) approved the protocol, and all
participants provided written consent.
Whole blood was collected into ethylene diamine
tetraacetic acid (EDTA) Vacutainers (VWR, Radnor, PA,
USA) at 0, 1, 3, and 6 h post-consumption on days 1
and 7 and on days 8, 9, and 14. After centrifuging at
2000 rpm for 30 min, plasma was removed, acidified
with trifluoroacetic acid, and stored at −80 °C. Samples
were analyzed for SFN metabolites as previously de-
scribed [27]. The remaining whole blood was processed
to isolate peripheral blood mononuclear cells (PBMC),
as described previously [12], and frozen at −80 °C.
Screening colonoscopy study
Men and women aged >50 years and scheduled for a
screening colonoscopy were recruited based on crucifer-
ous vegetable consumption (n = 28). Recruitment and
data collection were implemented through the Oregon
Clinical and Translational Research Institute and the
Oregon Health & Science University Cancer Institute,
with IRB approval and written consent from each par-
ticipant. Subjects completed a validated [28] cruciferous
vegetable food frequency questionnaire (CVFFQ) and
had three 24-h dietary recalls over a 3-week period. The
CVFFQ assessed intake over the previous 12 months, re-
lating to number of servings, serving size, intake of raw
and cooked vegetables, method of cooking, and use of
condiments. Data from the CVFFQ were analyzed by the
Arizona Diet, Behavioral, and Quality of Life Assessment
Center, University of Arizona, Tucson, AZ, USA. Volun-
teers were stratified into low (0–1 serving/week, n = 5)
and high (≥5 servings/week, n = 23) consumers. Dietary
recalls were used to provide information on possible
changes in diet between the CVFFQ and the clinic visit.
Blood was obtained and processed as in the BSE trial. In
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addition, two biopsies of rectal colon and two of prox-
imal colon were taken with standard forceps and placed
in formalin or flash-frozen in liquid nitrogen.
Statistics
Results were expressed as mean ± SD. Analysis of variance
(ANOVA) was used for group comparisons, followed by
Bonferroni’s multiple comparison test (GraphPad Prism v
5.04). Student’s t test was used for paired comparisons,
with P < 0.05 considered as significant.
Additional files
Additional file 1: Table S1. Gene expression changes in mouse colon.
The Table shows gene expression data of '84 genes' in the RT2 Profiler
array as described in Methods. Each colum (as labeled) provides a list of
the different genes, gene names, and the gene expression data (relative
to ACTB) normalized to normal colon in WT vehicle control mice
calculated using the RT2 Profier PCR Array Data Analysis software. Each
row provides data for a single gene, positive values indicating higher
expression whereas negative values indicating lower gene expression
compared to normal colon in WT vehicle controls. (DOCX 30 kb)
Additional file 2: Figure S1. Validation of gene array data in mouse
colon tumors and normal colon. a–d Relative mRNA expression of
selected genes normalized to the β-actin gene (Actb) in normal colonic
mucosa, and e–h in DMH-induced colon tumors. Data = mean ± SD
(n = 3). Red arrow, p16. Figure S2. HDAC3 interactions with Esr1 are
unaffected by SFN. Primers were designed to interrogate the promoter
region adjacent to the transcriptional start site of Esr1, a gene strongly
overexpressed in DMH-induced colon tumors (see Fig. 5b). ChIP
data = mean ± SD from three independent ChIP assays. Esr1 served as a
negative control for the ChIP assays with p16 (see Fig. 6f). Figure S3. SFN
altered HDAC3 and p16 expression in mouse splenocytes. Mice (n = 3)
were administered a single oral gavage of 200 μmol SFN, and mononuclear
cells were isolated from mouse spleen at 6 h, as reported earlier [12]. a Whole
cell lysates were immunoblotted for HDAC3, p16, and AcH4K12 with
densitometry data normalized to β-actin. b A colon tumor from
DMH-treated mice was included as a reference control. Figure S4. No
change in the expression of genes involved in DMH activation (Cyp2E1)
and DNA repair (Mgmt). Relative mRNA expression levels were normalized
to the β-actin gene, Actb. Data = mean ± SD (n = 3). Figure S5. Working
model for Nrf2 status impacting tumor growth, HDAC3 levels, and p16 in-
duction. (PPTX 276 kb)
Additional file 3: Table S2. SFN and its metabolites in human plasma
following ingestion of a BSE supplement. The levels of "SFN and its
metabolites" in human plasma was measured using Liquid
Chromatrography-Mass Spectrometry (LC-MS) methods, as described pre-
viously [27]. Calculated pharmacokinetic parameters - Tmax, Cmax, AUC,
and half-life (mean) values are shown in 'rows' for each SFN metabolite,
measured on Days 1 and 7, shown in respective columns. (DOCX 19 kb)
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